Aardvark Therapeutics, Inc.
AARD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001774857
In the last 90 days, Aardvark Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $54.3M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Aardvark Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +27 vs. Q4 2024
- Shares held
- 8.69M
- +8.69M vs. Q4 2024
- Total value
- $65.1M
- +$65.1M vs. Q4 2024
- New holders
- 27
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AARD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 71 | $54.3M |
| Q1 2026 | 79 | $38.5M |
| Q4 2025 | 66 | $141.0M |
| Q3 2025 | 49 | $125.7M |
| Q2 2025 | 35 | $120.5M |
| Q1 2025 | 27 | $65.1M |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Aardvark Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Decheng Capital LLC | 3,917,299 | $29.4M | 8.25% | +3,917,299 | New |
| Citadel Advisors LLC | 1,274,084 | $9.44M | 0.01% | +1,274,084 | New |
| Laurion Capital Management LP | 808,243 | $6.07M | 0.47% | +808,243 | New |
| Cormorant Asset Management, LP | 800,189 | $6.01M | 0.45% | +800,189 | New |
| Braidwell LP | 500,000 | $3.75M | 0.13% | +500,000 | New |
| Suvretta Capital Management, LLC | 312,500 | $2.35M | 0.09% | +312,500 | New |
| Adage Capital Partners GP, L.L.C. | 250,000 | $1.88M | 0.00% | +250,000 | New |
| Vanguard Group Inc | 165,491 | $1.24M | 0.00% | +165,491 | New |
| Schonfeld Strategic Advisors LLC | 143,951 | $1.08M | 0.01% | +143,951 | New |
| Silverarc Capital Management, LLC | 119,496 | $897.4K | 0.19% | +119,496 | New |
| Cantor Fitzgerald, L. P. | 66,682 | $500.8K | 0.02% | +66,682 | New |
| Millennium Management LLC | 65,640 | $493.0K | 0.00% | +65,640 | New |
| Geode Capital Management, LLC | 59,600 | $447.6K | 0.00% | +59,600 | New |
| Balyasny Asset Management LLC | 35,435 | $266.1K | 0.00% | +35,435 | New |
| BNP Paribas Arbitrage, SA | 34,690 | $260.5K | 0.00% | +34,690 | New |
| Goldman Sachs Group Inc | 20,311 | $152.5K | 0.00% | +20,311 | New |
| BlackRock, Inc. | 18,776 | $141.0K | 0.00% | +18,776 | New |
| Two Sigma Investments, LP | 15,424 | $115.8K | 0.00% | +15,424 | New |
| UBS Group AG | 14,705 | $110.4K | 0.00% | +14,705 | New |
| Squarepoint Ops LLC | 14,186 | $106.5K | 0.00% | +14,186 | New |
| Northern Trust Corp | 14,001 | $105.1K | 0.00% | +14,001 | New |
| Point72 (DIFC) Ltd | 12,797 | $96.1K | 0.01% | +12,797 | New |
| Walleye Capital LLC | 11,730 | $88.1K | 0.00% | +11,730 | New |
| Bank of America Corp | 4,620 | $34.7K | 0.00% | +4,620 | New |
| JPMorgan Chase & Co | 3,100 | $23.3K | 0.00% | +3,100 | New |
| Morgan Stanley | 2,218 | $16.7K | 0.00% | +2,218 | New |
| Point72 Asia (Singapore) Pte. Ltd. | 1,284 | $9.64K | 0.00% | +1,284 | New |